Literature DB >> 17367258

Naloxone treatment in opioid addiction: the risks and benefits.

Eveline L A van Dorp1, Ashraf Yassen, Albert Dahan.   

Abstract

Naloxone is a non-selective, short-acting opioid receptor antagonist that has a long clinical history of successful use and is presently considered a safe drug over a wide dose range (up to 10 mg). In opioid-dependent patients, naloxone is used in the treatment of opioid-overdose-induced respiratory depression, in (ultra)rapid detoxification and in combination with buprenorphine for maintenance therapy (to prevent intravenous abuse). Risks related to naloxone use in opioid-dependent patients are: i) the induction of an acute withdrawal syndrome (the occurrence of vomiting and aspiration is potentially life threatening); ii) the effect of naloxone may wear off prematurely when used for treatment of opioid-induced respiratory depression; and iii) in patients treated for severe pain with an opioid, high-dose naloxone and/or rapidly infused naloxone may cause catecholamine release and consequently pulmonary edema and cardiac arrhythmias. These risks warrant the cautious use of naloxone and adequate monitoring of the cardiorespiratory status of the patient after naloxone administration where indicated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367258     DOI: 10.1517/14740338.6.2.125

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  45 in total

1.  In Response to: "The Evolution of Recommended Naloxone Dosing for Opioid Overdose by Medical Specialty".

Authors:  Juliana Lombardi; Eric Villeneuve; Sophie Gosselin
Journal:  J Med Toxicol       Date:  2016-10-24

2.  The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice.

Authors:  Dipesh M Navani; Sunil Sirohi; Priyanka A Madia; Byron C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2011-06-29       Impact factor: 3.533

3.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

4.  In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.

Authors:  Samuel Obeng; Yunyun Yuan; Abdulmajeed Jali; Dana E Selley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2018-03-09       Impact factor: 4.432

5.  Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Authors:  Samuel Obeng; Abdulmajeed Jali; Yi Zheng; Huiqun Wang; Kathryn L Schwienteck; Chongguang Chen; David L Stevens; Hamid I Akbarali; William L Dewey; Mathew L Banks; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2019-02-21       Impact factor: 4.418

6.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

7.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

Review 8.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

9.  Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Authors:  Yi Zheng; Samuel Obeng; Bethany A Reinecke; Chongguang Chen; Palak S Phansalkar; David M Walentiny; Phillip M Gerk; Lee-Yuan Liu-Chen; Dana E Selley; Patrick M Beardsley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2019-11-16       Impact factor: 4.432

10.  The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.

Authors:  Sunil Sirohi; Shveta V Dighe; Priyanka A Madia; Byron C Yoburn
Journal:  J Pharmacol Exp Ther       Date:  2009-05-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.